Nailfold capillary morphology and platelet function in patients with exfoliative glaucoma.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
12
2018
accepted:
25
06
2019
entrez:
10
7
2019
pubmed:
10
7
2019
medline:
3
3
2020
Statut:
epublish
Résumé
The purpose of the present study was to evaluate the nailfold capillary morphological features in patients with exfoliative glaucoma (XFG) and compare them with those pertaining to primary open-angle glaucoma (POAG), normal controls and subjects with exfoliation syndrome (XFS). The second purpose was to investigate all parameters related to platelet function on the hemogram, including the platelet count (PLT), the mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in patients with XFG. These parameters were subsequently compared with those belonging to normal controls, POAG and XFS subjects. This case control study involved 152 consecutive patients that were examined at the Glaucoma Department of Clinic for Eye Diseases, Clinical Centre of Serbia, as the referral center for glaucoma in Serbia, between June 2016 and December 2017. Regarding capillaroscopic characteristics, statistically significant difference was found in capillary diameter and tortuosity between the XFG and POAG group (p = 0.050 and p = 0.035) and the XFG and NC group (p = 0.003 and p = 0.044), as well as in the distribution of capillary loops and avascular zones between the XFG and NC group (p = 0.014 and p = 0.004). The subjects with XFG had lower PLT values compared to POAG patients (p = 0.022). In conclusion, to the best of our knowledge, this study marks the first attempt to evaluate capillary morphology as well as to investigate all parameters related to platelet function on the hemogram, in patients with newly diagnosed XFG. Our findings revealed nailfold capillary morphological vascular changes in XFG patients. The subjects with XFG had lower PLT values and a higher MPV serum parameter compared to normal controls and patients with POAG. Further research in this field should therefore aim to evaluate the consequences of the aforementioned microvascular abnormalities in patients with XFG.
Identifiants
pubmed: 31287835
doi: 10.1371/journal.pone.0219505
pii: PONE-D-18-36660
pmc: PMC6615605
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0219505Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
World J Cardiol. 2014 Aug 26;6(8):847-54
pubmed: 25228963
Diabet Med. 2011 Sep;28(9):1039-44
pubmed: 21517956
Am J Ophthalmol. 2006 May;141(5):921-937
pubmed: 16678509
Curr Eye Res. 2010 Dec;35(12):1099-104
pubmed: 20929293
Eye (Lond). 2017 May;31(5):698-707
pubmed: 28085140
Semin Vasc Med. 2003 May;3(2):147-62
pubmed: 15199478
Ophthalmology. 1995 Sep;102(9):1279-90
pubmed: 9097764
Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):1067-74
pubmed: 22134713
Clin Exp Ophthalmol. 2008 Nov;36(8):738-43
pubmed: 19128378
J Glaucoma. 2008 Mar;17(2):133-8
pubmed: 18344760
Br J Ophthalmol. 2012 Aug;96(8):1137-40
pubmed: 22730511
Eye Contact Lens. 2016 Sep;42(5):328-32
pubmed: 26448448
J Thromb Thrombolysis. 2010 Oct;30(3):251-62
pubmed: 20502945
Clin Exp Rheumatol. 1995 Jan-Feb;13(1):83-6
pubmed: 7774109
Semin Arthritis Rheum. 1999 Aug;29(1):36-42
pubmed: 10468413
Acta Reumatol Port. 2007 Jan-Mar;32(1):29-36
pubmed: 17450762
Clin Rheumatol. 2015 Feb;34(2):279-84
pubmed: 25318613
JAMA Ophthalmol. 2019 Jun 1;137(6):618-625
pubmed: 30973595
Br J Dermatol. 1997 Jan;136(1):94-6
pubmed: 9039302
J Glaucoma. 1998 Apr;7(2):105-10
pubmed: 9559496
Mol Vis. 2010 Feb 06;16:167-77
pubmed: 20142848
Br J Ophthalmol. 2006 May;90(5):563-7
pubmed: 16488931
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1853-61
pubmed: 23754794
Best Pract Res Clin Rheumatol. 2008 Dec;22(6):1093-108
pubmed: 19041079
Thromb Res. 2006;117(4):371-7
pubmed: 15935453
Thromb Res. 2009 Feb;123(4):587-91
pubmed: 18472144
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7021-8
pubmed: 26523386
Acta Ophthalmol. 2016 Sep;94(6):e505-12
pubmed: 26648185
Acta Ophthalmol. 2010 Feb;88(1):91-5
pubmed: 19725816
J Glaucoma. 2018 Jul;27 Suppl 1:S72-S74
pubmed: 29419648
Curr Pharm Des. 2011;17(1):47-58
pubmed: 21247392
Rev Bras Reumatol. 2015 May-Jun;55(3):264-71
pubmed: 25440704
Br J Ophthalmol. 2019 Feb;103(2):203-207
pubmed: 29699986
J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S9-11
pubmed: 25275916
Arch Ophthalmol. 2011 Oct;129(10):1299-304
pubmed: 21987672
J Clin Invest. 2005 Dec;115(12):3378-84
pubmed: 16322783
Science. 2007 Sep 7;317(5843):1397-400
pubmed: 17690259
Invest Ophthalmol Vis Sci. 2011 Oct 31;52(11):8488-95
pubmed: 21948647
Br J Ophthalmol. 1983 Apr;67(4):249-54
pubmed: 6187357
Eye (Lond). 2011 Feb;25(2):174-9
pubmed: 21127507
Ann Nutr Metab. 2015;67(1):1-12
pubmed: 26201664
Nat Genet. 2004 Feb;36(2):178-82
pubmed: 14745449
Int Heart J. 2006 Jan;47(1):77-84
pubmed: 16479043
Ophthalmology. 1987 Sep;94(9):1090-7
pubmed: 2446230
Surv Ophthalmol. 2001 Jan-Feb;45(4):265-315
pubmed: 11166342
Curr Eye Res. 2013 Feb;38(2):266-70
pubmed: 23330805
Eur J Ophthalmol. 2014 Jan-Feb;24(1):71-5
pubmed: 23813107
J Thromb Haemost. 2010 Jan;8(1):148-56
pubmed: 19691485
Clin Interv Aging. 2015 May 20;10:879-83
pubmed: 26056437
Acta Ophthalmol Scand. 2004 Dec;82(6):738-40
pubmed: 15606473
Arthritis Rheum. 1981 Sep;24(9):1159-65
pubmed: 7306237
Korean J Ophthalmol. 2009 Dec;23(4):296-300
pubmed: 20046692